316 related articles for article (PubMed ID: 12810680)
1. EphA2 overexpression decreases estrogen dependence and tamoxifen sensitivity.
Lu M; Miller KD; Gokmen-Polar Y; Jeng MH; Kinch MS
Cancer Res; 2003 Jun; 63(12):3425-9. PubMed ID: 12810680
[TBL] [Abstract][Full Text] [Related]
2. Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer.
Gökmen-Polar Y; Toroni RA; Hocevar BA; Badve S; Zhao Q; Shen C; Bruckheimer E; Kinch MS; Miller KD
Breast Cancer Res Treat; 2011 Jun; 127(2):375-84. PubMed ID: 20602165
[TBL] [Abstract][Full Text] [Related]
3. Benefits of complete polyamine deprivation in hormone responsive and hormone resistant MCF-7 human breast adenocarcinoma in vivo.
Leveque J; Foucher F; Havouis R; Desury D; Grall JY; Moulinoux JP
Anticancer Res; 2000; 20(1A):97-101. PubMed ID: 10769640
[TBL] [Abstract][Full Text] [Related]
4. Estrogen and Myc negatively regulate expression of the EphA2 tyrosine kinase.
Zelinski DP; Zantek ND; Walker-Daniels J; Peters MA; Taparowsky EJ; Kinch MS
J Cell Biochem; 2002; 85(4):714-20. PubMed ID: 11968011
[TBL] [Abstract][Full Text] [Related]
5. mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen.
Revillion F; Pawlowski V; Lhotellier V; Louchez MM; Peyrat JP
Anticancer Res; 2003; 23(2B):1455-60. PubMed ID: 12820409
[TBL] [Abstract][Full Text] [Related]
6. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
[TBL] [Abstract][Full Text] [Related]
7. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.
Pietras RJ; Arboleda J; Reese DM; Wongvipat N; Pegram MD; Ramos L; Gorman CM; Parker MG; Sliwkowski MX; Slamon DJ
Oncogene; 1995 Jun; 10(12):2435-46. PubMed ID: 7784095
[TBL] [Abstract][Full Text] [Related]
8. Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells.
Bindels EM; Lallemand F; Balkenende A; Verwoerd D; Michalides R
Oncogene; 2002 Nov; 21(53):8158-65. PubMed ID: 12444551
[TBL] [Abstract][Full Text] [Related]
9. Differential EphA2 epitope display on normal versus malignant cells.
Coffman KT; Hu M; Carles-Kinch K; Tice D; Donacki N; Munyon K; Kifle G; Woods R; Langermann S; Kiener PA; Kinch MS
Cancer Res; 2003 Nov; 63(22):7907-12. PubMed ID: 14633720
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3.
Ishii Y; Waxman S; Germain D
Cancer Res; 2008 Feb; 68(3):852-60. PubMed ID: 18245487
[TBL] [Abstract][Full Text] [Related]
11. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
[TBL] [Abstract][Full Text] [Related]
12. Estrogen-stimulation of postconfluent cell accumulation and foci formation of human MCF-7 breast cancer cells.
Gierthy JF; Lincoln DW; Roth KE; Bowser SS; Bennett JA; Bradley L; Dickerman HW
J Cell Biochem; 1991 Feb; 45(2):177-87. PubMed ID: 2055945
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen, flaxseed, and the lignan enterolactone increase stroma- and cancer cell-derived IL-1Ra and decrease tumor angiogenesis in estrogen-dependent breast cancer.
Lindahl G; Saarinen N; Abrahamsson A; Dabrosin C
Cancer Res; 2011 Jan; 71(1):51-60. PubMed ID: 21097717
[TBL] [Abstract][Full Text] [Related]
14. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
15. Reversal of an antiestrogen-mediated cell cycle arrest of MCF-7 cells by viral tumor antigens requires the retinoblastoma protein-binding domain.
Varma H; Conrad SE
Oncogene; 2000 Sep; 19(41):4746-53. PubMed ID: 11032025
[TBL] [Abstract][Full Text] [Related]
16. High tumoral levels of Kiss1 and G-protein-coupled receptor 54 expression are correlated with poor prognosis of estrogen receptor-positive breast tumors.
Marot D; Bieche I; Aumas C; Esselin S; Bouquet C; Vacher S; Lazennec G; Perricaudet M; Kuttenn F; Lidereau R; de Roux N
Endocr Relat Cancer; 2007 Sep; 14(3):691-702. PubMed ID: 17914099
[TBL] [Abstract][Full Text] [Related]
17. MCF-7 breast carcinoma cells overexpressing FGF-1 form vascularized, metastatic tumors in ovariectomized or tamoxifen-treated nude mice.
Zhang L; Kharbanda S; Chen D; Bullocks J; Miller DL; Ding IY; Hanfelt J; McLeskey SW; Kern FG
Oncogene; 1997 Oct; 15(17):2093-108. PubMed ID: 9366526
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of PKCalpha is required to impart estradiol inhibition and tamoxifen-resistance in a T47D human breast cancer tumor model.
Lin X; Yu Y; Zhao H; Zhang Y; Manela J; Tonetti DA
Carcinogenesis; 2006 Aug; 27(8):1538-46. PubMed ID: 16513679
[TBL] [Abstract][Full Text] [Related]
19. Cyr61 promotes breast tumorigenesis and cancer progression.
Tsai MS; Bogart DF; Castañeda JM; Li P; Lupu R
Oncogene; 2002 Nov; 21(53):8178-85. PubMed ID: 12444554
[TBL] [Abstract][Full Text] [Related]
20. Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites.
Liu X; Pisha E; Tonetti DA; Yao D; Li Y; Yao J; Burdette JE; Bolton JL
Chem Res Toxicol; 2003 Jul; 16(7):832-7. PubMed ID: 12870885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
